Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits. Large vector doses also trigger an immune response as a significant fraction of the vectors fails to traffic efficiently to the nucleus and is targeted for degradation by the host cell proteasome machinery. We have reported that epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) signaling negatively affects transduction by AAV2 vectors by impairing nuclear transport of the vectors. We have also observed that EGFR-PTK can phosphorylate AAV2 capsids at tyrosine residues. Tyrosine-phosphorylated AAV2 vectors enter cells efficiently but fail to transduce effectively, in part because of ubiquitination of AAV capsids followed by proteasome-mediated degradation. We reasoned that mutations of the surface-exposed tyrosine residues might allow the vectors to evade phosphorylation and subsequent ubiquitination and, thus, prevent proteasome-mediated degradation. Here, we document that site-directed mutagenesis of surface-exposed tyrosine residues leads to production of vectors that transduce HeLa cells ≈10-fold more efficiently in vitro and murine hepatocytes nearly 30-fold more efficiently in vivo at a log lower vector dose. Therapeutic levels of human Factor IX (F.IX) are also produced at an ≈10-fold reduced vector dose. The increased transduction efficiency of tyrosine-mutant vectors is due to lack of capsid ubiquitination and improved intracellular trafficking to the nucleus. These studies have led to the development of AAV vectors that are capable of high-efficiency transduction at lower doses, which has important implications in their use in human gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous mutagenesis and biophysical studies have reported the importance of some of these residues in virus assembly, production (Grieger et al., 2006; Wu et al., 2000), infectivity (Zhong et al., 2008), and pH-induced changes during trafficking (Nam et al., 2011; Salganik et al., 2012).”
From Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2 (2020) · cites this paper as Zhong et al., 2008
In the citing paper
“Therefore, mutation of surface tyrosine has been suggested, which resulted in reduced presentation of AAV capsid, decreased T-cell toxicity, and required therapeutic dose [100, 225, 229].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [229]
In the citing paper
“Since surface-exposed residues on AAV capsids can be ubiquitinated through phosphorylation, mutations of these residues (e.g. tyrosine, lysine, serine) to reduce the likelihood of ubiquitination can generate novel capsids with reduced ubiquitination, antigen presentation, and activated cellular immunity (92 -99).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [93]
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648 · cited 1×
“The icosahedral two-, three- and fivefold related VP3 monomers were generated by applying icosahedral symmetry operators to a reference monomer, using the program O (46) on a Silicon graphics Octane workstation.”
MethodManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Self-citationXiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells
Muzyczka, N. (1992) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-75608-5_5 · Cited by 754 · cited 1×
“T adeno-associated virus 2 (AAV2) is a nonpathogenic human parvovirus, which has gained attention as an alternative to the more commonly used retrovirus- and adenovirusbased vectors for gene transfer and gene therapy (1, 2).”
BackgroundSelf-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“It was concluded that this CD8 T cell response to input capsid eliminated AAV2-transduced hepatocytes (43).”
BackgroundαVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
“This seminal work led to the demonstration that AAV vectors could also efficiently transduce a variety of target tissues in animal models, including liver, retina, cardiac muscle, and central nervous system, with specific tissue tropisms discovered for several naturally occurring AAV serotypes and AAV engineered with…”
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
“Studies have shown that mutation of tyrosine to phenylalanine, which prevents this phosphorylation, results in dramatically improved transduction efficiencies [63].”
BackgroundEngineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“94 Evidence continued to emerge to support the hypothesis that presentation via MHC I pathways of the preformed capsid antigen had led to immune-mediated destruction of transduced hepatocytes.”
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“65 Modifying these residues to phenylalanine (Y444F/Y500F/Y730F) increased gene delivery in the CNS. 66 While rAAV2 is not able to transduce photoreceptors through intravitreal injection, a variant containing substitutions of speci fi c residues (Y272F/Y444F/Y500F/Y730F/T491V) achieved transduction…”
BackgroundEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
“The mutations of specific tyrosine,(110) serine, threonine, and lysine(111) residues on various AAV capsids have been reported as an efficient strategy to increase the vector load that reaches the nucleus by de-targeting the viral particles from proteasomal degradation.(110,111) Improved liver transduction and faster…”
BackgroundEngineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
State-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
“Improved vectors have also been obtained by experimentally modifying the capsid sequence with site-specific mutations, by using hybrid capsid”
AAV-Mediated Gene Therapy for Research and Therapeutic Purposes
Samulski, R. J., & Muzyczka, N. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085355 · Cited by 551
Self-citationThe AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Viral Vectors for Gene Therapy: Translational and Clinical Outlook
Kotterman, M. A., Chalberg, T. W., & Schaffer, D. V. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104938 · Cited by 424
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
Self-citationAAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
“64,65 A triple-mutant (Y444F + Y500F + Y730F) vector has (cid:1) 30-to 80-fold higher level of in vivo gene transfer to murine hepatocytes 66 and (cid:1) 130-fold increase in transgene expression in murine fi broblasts 67 than the wild-type AAV2.”
BackgroundInner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357
Hastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
Doroudchi, M. M., Greenberg, K. P., Liu, J., Silka, K. A., Boyden, E. S., Lockridge, J. A., Arman, A. C., Janani, R., Boye, S. E., Boye, S. L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.69 · Cited by 277
Ayuso, E., Mingozzi, F., Montane, J., Leon, X., Anguela, X. M., Haurigot, V, Edmonson, S. A., Africa, L., Zhou, S., High, K. A., et al. (2010) · Gene Therapy · doi:10.1038/gt.2009.157 · Cited by 272
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267
Self-citationCapsid modifications for targeting and improving the efficacy of AAV vectors
Büning, H., & Srivastava, A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.008 · Cited by 260
“Zhong et al.93 mutagenized each of these Y residues to phenylalanine (F) residues because F residues cannot be phosphorylated by cellular tyrosine kinase as F lacks the hydroxyl (OH) group.”
BackgroundInfluentialSelf-citationIntracellular transport of recombinant adeno-associated virus vectors
Nonnenmacher, M., & Weber, T. (2012) · Gene Therapy · doi:10.1038/gt.2012.6 · Cited by 258
Pharmacogenetic Modulation of Orexin Neurons Alters Sleep/Wakefulness States in Mice
Sasaki, K., Suzuki, M., Mieda, M., Tsujino, N., Roth, B., & Sakurai, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020360 · Cited by 249
“Briefly, 293A cells (Invitrogen), cultured in ten 100620 mm cell culture dishes per viral vector, were transfected with pHelper (Stratagene), pACG-2-Y730F [24] (containing a mutant form of the cap gene of AAV2 and provided by Dr.”
MethodMartino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246
Self-citationAdeno-associated virus (AAV) vectors in cancer gene therapy
Santiago-Ortiz, J. L., & Schaffer, D. V. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.001 · Cited by 228
Zhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., et al. (2008) · Virology · doi:10.1016/j.virol.2008.08.027 · Cited by 232
“…a cellular chaperone protein, FKBP52, is phosphorylated at tyrosine residues by EGFR-PTK, and that tyrosine-phosphorylated FKBP52 strongly inhibits the viral second-strand DNA synthesis, and consequently the transgene expression (Qing et al., 2001, 2003; Zhong et al., 2004a, 2004b, 2004d, 2008b).”
BackgroundSelf-citationBasic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy
Balakrishnan, B., & Jayandharan, G. (2014) · Current Gene Therapy · doi:10.2174/1566523214666140302193709 · Cited by 225
“Mutagenesis of the surface exposed tyrosine to phenylalanine amino acids on the AAV2 capsid have been shown to improve their transduction by ~ 10 fold [176, 177], while modifications at specific serine, threonine or lysine residues improved the transgene expression of various serotypes (AAV1, AAV2, AAV5 and AAV8) by s…”
den Hollander, A. I., Black, A., Bennett, J., & Cremers, F. P. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42258 · Cited by 207
AAV Capsid Structure and Cell Interactions
Agbandje-McKenna, M., & Kleinschmidt, J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_3 · Cited by 215
Self-citationPharmaceutical development of AAV-based gene therapy products for the eye
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2554-7 · Cited by 213
“This in turn leads to enhanced nuclear transport and increased transgene expression (72).”
BackgroundWang, L., Calcedo, R., Bell, P., Lin, J., Grant, R. L., Siegel, D. L., & Wilson, J. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.031 · Cited by 212
“Improved transduction efficiencies have been achieved with second-generation vector technologies such as pseudotyped lentiviruses and novel adeno-associated virus (AAV) sero-types (Kobinger et al. , 2001; Gao et al. , 2002; Zhong et al. , 2008).”
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9
Saraiva, J., Nobre, R. J., & Pereira de Almeida, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.011 · Cited by 201
Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications
Grieger, J. C., & Samulski, R. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00012-0 · Cited by 199
“A final set of rationally designed vectors was engineered by Petrs-Silva et al. (2009) and Zhong et al. (2008b).”
BackgroundTwenty-Five Years of Structural Parvovirology
Mietzsch, M., Pénzes, J. J., & Agbandje-McKenna, M. (2019) · Viruses · doi:10.3390/v11040362 · Cited by 197
“Mutational analysis of these tyrosine residues to phenylalanine led to the development of engineered capsids that showed improved transduction efficiencies compared to vectors packaged into wt capsids [126].”
BackgroundMethodInfluentialSelf-citationVector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183
“Phosphorylation of specific tyrosine residues within the AAV capsid is thought to be responsible for AAV targeting to proteasome and degradation (Zhong et al., 2008a).”
BackgroundInnate Immune Responses to AAV Vectors
Rogers, G. L., Martino, A. T., Aslanidi, G. V., Jayandharan, G. R., Srivastava, A., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00194 · Cited by 178
“REVIEW ARTICLE published: 19 September 2011 doi: 10.3389/fmicb.2011.00194 Innate immune responses to AAV vectors”
BackgroundInfluentialSelf-citationAdeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Orexin neurons suppress narcolepsy via 2 distinct efferent pathways
Hasegawa, E., Yanagisawa, M., Sakurai, T., & Mieda, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71017 · Cited by 161
Kotterman, M. A., Yin, L., Strazzeri, J. M., Flannery, J. G., Merigan, W. H., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2014.115 · Cited by 169
Directed evolution of novel adeno-associated viruses for therapeutic gene delivery
Bartel, M. A., Weinstein, J. R., & Schaffer, D. V. (2012) · Gene Therapy · doi:10.1038/gt.2012.20 · Cited by 162
Viral Strategies for Targeting the Central and Peripheral Nervous Systems
Bedbrook, C. N., Deverman, B. E., & Gradinaru, V. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-062048 · Cited by 168
Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors
Kay, C. N., Ryals, R. C., Aslanidi, G. V., Min, S. H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D., Ayala, A. E., Van Vliet, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062097 · Cited by 168
“Selected tyrosine residues were mutated to phenylalanine (Y2F) whereas threonine residues were mutated to valine (T2V) [27].”
MethodSelf-citationMartino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
“These results are in agreement with previously published work showing that tyrosine mutant AAV2 traffics more efficiently to the nucleus.(35,42) Figure 1.”
BackgroundResultInfluentialSelf-citationLau, C.-H., & Suh, Y. (2017) · F1000Research · doi:10.12688/f1000research.11243.1 · Cited by 161
Silva, S. R. D., Arno, G., Robson, A. G., Fakin, A., Pontikos, N., Mohamed, M. D., Bird, A. C., Moore, A. T., Michaelides, M., Webster, A. R., et al. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100898 · Cited by 164
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Therefore, mutation of surface tyrosine has been suggested, which resulted in reduced presentation of AAV capsid, decreased T-cell toxicity, and required therapeutic dose [100, 225, 229].”
BackgroundAdachi, K., Enoki, T., Kawano, Y., Veraz, M., & Nakai, H. (2014) · Nature Communications · doi:10.1038/ncomms4075 · Cited by 154
Pang, J., Dai, X., Boye, S. L., Barone, I., Boye, S. L., Mao, S., Everhart, D., Dinculescu, A., Liu, L., Umino, Y., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.273 · Cited by 154
Sahel, J., & Roska, B. (2013) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062012-170304 · Cited by 169
“…than 100 different natural capsids, and thousands of genetically modified capsids have been created through rational mutagenesis of the capsid (PetrsSilva et al. 2009, 2011; Zhong et al. 2008) or selected through combinatorial screens (Bartel et al. 2012, Dalkara et al. 2011, Klimczak et al. 2009).”
BackgroundAddressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’
Kishimoto, T. K., & Samulski, R. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2060737 · Cited by 152
Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids
Castle, M. J., Turunen, H. T., Vandenberghe, L. H., & Wolfe, J. H. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_10 · Cited by 151
Viral Vectors for Gene Transfer
Chen, Y. H., Keiser, M. S., & Davidson, B. L. (2018) · Current Protocols in Mouse Biology · doi:10.1002/cpmo.58 · Cited by 146
Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges
Maes, M. E., Colombo, G., Schulz, R., & Siegert, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134310 · Cited by 145
Hellström, M., Ruitenberg, M. J., Pollett, M. A., Ehlert, E. M. E., Twisk, J., Verhaagen, J., & Harvey, A. R. (2009) · Gene Therapy · doi:10.1038/gt.2008.178 · Cited by 142
AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression
Ding, K., Shen, J., Hafiz, Z., Hackett, S. F., Silva, R. L. E., Khan, M., Lorenc, V. E., Chen, D., Chadha, R., Zhang, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129085 · Cited by 141
“Mutant AAV vectors, in which surface tyrosine residues involved in ubiquitination are replaced with phenylalanines, reduce vector degradation and increase transgene expression at lower vector doses, increasing effectiveness of small amounts of vector that penetrate the ILM (34, 35).”
BackgroundAdeno-Associated Virus Gene Therapy for Liver Disease
Kattenhorn, L. M., Tipper, C. H., Stoica, L., Geraghty, D. S., Wright, T. L., Clark, K. R., & Wadsworth, S. C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.160 · Cited by 138
Adeno-Associated Viral Vectors and Their Redirection to Cell-Type Specific Receptors
Michelfelder, S., & Trepel, M. (2009) · Advances in genetics · doi:10.1016/s0065-2660(09)67002-4 · Cited by 149
Microdystrophin Ameliorates Muscular Dystrophy in the Canine Model of Duchenne Muscular Dystrophy
Shin, J., Pan, X., Hakim, C. H., Yang, H. T., Yue, Y., Zhang, K., Terjung, R. L., & Duan, D. (2013) · Molecular Therapy · doi:10.1038/mt.2012.283 · Cited by 146
Markusic, D. M., Herzog, R. W., Aslanidi, G. V., Hoffman, B. E., Li, B., Li, M., Jayandharan, G. R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.172 · Cited by 131
Self-citationNovel adeno-associated viral vectors for retinal gene therapy.
Vandenberghe, L. H., & Auricchio, A. (2012) · Gene Therapy · doi:10.1038/gt.2011.151 · Cited by 131
AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
Rogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131
Self-citationIntracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions
Riyad, J. M., & Weber, T. (2021) · Gene Therapy · doi:10.1038/s41434-021-00243-z · Cited by 146
Viral Vectors and Delivery Strategies for CNS Gene Therapy
Gray, S. J., Woodard, K., & Samulski, R. J. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.50 · Cited by 135
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
“For example, AAV capsids with reduced surface exposed tyrosine residues showed reduced capsid-specific CTL responses in vitro and in nonclinical studies in mice, assuming a reduction in MHC (cross-) presentation.(18,19)”
BackgroundMassively parallel cis-regulatory analysis in the mammalian central nervous system
Shen, S. Q., Myers, C. A., Hughes, A. E. O., Byrne, L. C., Flannery, J. G., & Corbo, J. C. (2015) · Genome Research · doi:10.1101/gr.193789.115 · Cited by 138
Yue, Y., Pan, X., Hakim, C. H., Kodippili, K., Zhang, K., Shin, J., Yang, H. T., McDonald, T., & Duan, D. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv310 · Cited by 131
Soya, S., Shoji, H., Hasegawa, E., Hondo, M., Miyakawa, T., Yanagisawa, M., Mieda, M., & Sakurai, T. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1130-13.2013 · Cited by 126
“Orexin neurons receive input from the limbic system (Winsky-Sommerer et al., 2004; Sakurai et al., 2005; Yoshida et al., 2006).”
BackgroundAdeno-associated Virus Vectors in Gene Therapy
Mary, B., Khan, N., Arumugam, S., Saxena, H., Kumar, M., Manimaran, P., Chattopadhyay, S., & Jayandharan, G. R. (2018) · Springer eBooks · doi:10.1007/978-981-13-0481-1_2 · Cited by 127
Monahan, P. E., Lothrop, C. D., Sun, J., Hirsch, M. L., Kafri, T., Kantor, B., Sarkar, R., Tillson, D. M., Elia, J. R., & Samulski, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.170 · Cited by 125
Sabatino, D. E., Lange, A. M., Altynova, E. S., Sarkar, R., Zhou, S., Merricks, E. P., Franck, H. W. G., Nichols, T. C., Arruda, V. R., & Kazazian, H. H. (2010) · Molecular Therapy · doi:10.1038/mt.2010.240 · Cited by 124
Journey to the Center of the Cell: Tracing the Path of AAV Transduction
Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.010 · Cited by 122
Engineering the AAV capsid to optimize vector–host-interactions
Büning, H., Huber, A., Zhang, L. N., Meumann, N., & Hacker, U. T. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.08.002 · Cited by 120
Microglia-specific targeting by novel capsid-modified AAV6 vectors
Rosario, A. M., Cruz, P. E., Ceballos‐Diaz, C., Strickland, M. R., Siemienski, Z. B., Pardo, M., Schob, K.-L., Li, A., Aslanidi, G., Srivastava, A., et al. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.26 · Cited by 123
Self-citationEffective gene therapy for haemophilic mice with pathogenic factor IX antibodies
Markusic, D. M., Hoffman, B. E., Perrin, G. Q., Nayak, S., Wang, X., LoDuca, P. A., High, K. A., & Herzog, R. W. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302859 · Cited by 116
“…and that can be further minimized by use of capsid sequences engineered to reduce MHC I presentation (Markusic et al, 2010; Martino et al, 2013; Zhong et al, 2008). is a critical component of the mechanism of tolerance induction by hepatic AAV gene transfer (Hoffman et al, 2011; Cao et al,…”
Self-citationO’Carroll, S. J., Cook, W. H., & Young, D. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.618020 · Cited by 125
Dalkara, D., Kolstad, K. D., Guerin, K. I., Hoffmann, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2011) · Molecular Therapy · doi:10.1038/mt.2011.62 · Cited by 115
Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid
Vercauteren, K., Hoffman, B. E., Zolotukhin, I., Keeler, G. D., Xiao, J. W., Basner-Tschakarjan, E., High, K. A., Ertl, H. C., Rice, C. M., Srivastava, A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.61 · Cited by 114
Self-citationAdeno-Associated Virus Structural Biology as a Tool in Vector Development
Drouin, L. M., & Agbandje-McKenna, M. (2013) · Future Virology · doi:10.2217/fvl.13.112 · Cited by 114
Self-citationHareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
“Identification of the immunogenic epitopes was initially done by peptide scanning to map neutralising epitopes for antibodies present in mice [84] or humans [85,86].”
BackgroundSelf-citationRetinal gene therapy with a large MYO7A cDNA using adeno-associated virus
Lopes, V. S., Boye, S. E., Louie, C. M., Boye, S., Dyka, F., Chiodo, V, Fofo, H., Hauswirth, W. W., & Williams, D. S. (2013) · Gene Therapy · doi:10.1038/gt.2013.3 · Cited by 112
Mao, Y., Wang, X., Yan, R., Hu, W., Li, A. I., Wang, S., & Li, H. (2016) · BMC Biotechnology · doi:10.1186/s12896-015-0230-0 · Cited by 111
“For example, the Y to F mutants of AAV2 can dramatically enhance gene transfer and expression both in vitro and in vivo [12, 13, 32].”
BackgroundMethodNam, H.-J., Gurda, B. L., McKenna, R., Potter, M., Byrne, B., Salganik, M., Muzyczka, N., & Agbandje-McKenna, M. (2011) · Journal of Virology · doi:10.1128/jvi.05305-11 · Cited by 108
“3), is one of seven capsid surfaceexposed tyrosine residues reported to be phosphorylated for subsequent ubiquitination and proteasomal degradation during AAV2 trafficking, resulting in reduced transduction of certain target cells which can be overcome by mutation to phenylalanine (52, 53).”
BackgroundSelf-citationMowat, F. M., Gornik, K. R., Dinculescu, A., Boye, S. L., Hauswirth, W. W., Petersen-Jones, S. M., & Bartoe, J. T. (2014) · Gene Therapy · doi:10.1038/gt.2013.64 · Cited by 108
Shen, S., Horowitz, E. D., Troupes, A. N., Brown, S. M., Pulicherla, N., Samulski, R. J., Agbandje‐McKenna, M., & Asokan, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.482380 · Cited by 107
“self-complementary vectors (36) or Tyr-to-Phe capsid mutations (37)) remains to be seen.”
BackgroundSelf-citationSystemic delivery of adeno-associated viral vectors
Duan, D. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.07.006 · Cited by 109
Mary, B., Maurya, S., Arumugam, S., Kumar, V. S., & Jayandharan, G. R. (2019) · FEBS Journal · doi:10.1111/febs.15013 · Cited by 108
Koilkonda, R. D., Yu, H., Chou, T.-H., Feuer, W. J., Ruggeri, M., Porciatti, V., Tse, D., Hauswirth, W. W., Chiodo, V. A., Boye, S. L., et al. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.7630 · Cited by 104
Ling, C., Lu, Y., Kalsi, J. K., Jayandharan, G. R., Li, B., Ma, W., Cheng, B., Gee, S. W. Y., McGoogan, K. E., Govindasamy, L., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.075 · Cited by 107
“…residues in the AAV3 capsid further improves the transduction efficiency of AAV3 serotype vectors in human liver cancer cells as well (our unpublished data), which is consistent with our published studies with tyrosine-mutant AAV2, AAV6, AAV8, and AAV9 serotype vectors (Zhong et al. , 2008; FIG.”
Self-citationCell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner‐Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 112
The potential of adeno-associated viral vectors for gene delivery to muscle tissue
Wang, D., Li, Z., Nahid, M. A., & Gao, G. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.871258 · Cited by 104
“The versatility and utility of rAAV vectors were further expanded by the natural or artificially evolved [15,16] diversity of AAV capsid proteins, which dictate the biological properties of rAAV such as cell or tissue tropism, biodistribution, host immune responses and so on.”
Viral Vectors for Gene Transfer: Current Status of Gene Therapeutics
Heilbronn, R., & Weger, S. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00477-3_5 · Cited by 100
AAV vector development, back to the future
Suárez-Amarán, L., Song, L., Tretiakova, A. P., Mikhail, S., & Samulski, R. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.064 · Cited by 101
“115 These modifications prevented phosphorylation and ubiquitination, enhancing nuclear trafficking and resulting in higher transduction efficiency at lower doses.”
Aslanidi, G., Rivers, A. E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Vliet, K. V., Tan, M., Agbandje‐McKenna, M., & Srivastava, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059142 · Cited by 98
“increase in transduction compared to WT AAV2 when of the seven surface-exposed tyrosines where mutated to phenylanine residues [13].”
BackgroundMethodResultInfluentialSelf-citationAAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
Mitchell, A. M., Nicolson, S. C., Warischalk, J. K., & Samulski, R. J. (2010) · Current Gene Therapy · doi:10.2174/156652310793180706 · Cited by 101
Acat1 Knockdown Gene Therapy Decreases Amyloid-β in a Mouse Model of Alzheimer's Disease
Murphy, S. R., Chang, C. C., Dogbevia, G., Bryleva, E. Y., Bowen, Z., Hasan, M. T., & Chang, T.-Y. (2013) · Molecular Therapy · doi:10.1038/mt.2013.118 · Cited by 96
“46 Neutralized formic acid extracts were used with the Human β Amyloid (1-42) ELISA kit (Wako Chemicals, Richmond, VA).”
InfluentialSalmon, F., Grosios, K., & Petry, H. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.852065 · Cited by 106
Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors
Pekrun, K., de Alencastro, G., Luo, Q.-J., Liu, J., Kim, Y., Nygaard, S. C., Galivo, F., Zhang, F., Song, R., Tiffany, M. R., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.131610 · Cited by 100
Zhang, Y., & Duan, D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.131 · Cited by 95
“The Y445F tyrosine modified AAV-6 was generated and purified using a previously reported protocol (Zhong et al., 2008; Qiao et al., 2010).”
BackgroundMethod
Metadata
- Authors
- Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., Muzyczka, N., & Srivastava, A.
- Affiliations
- *Division of Cellular and Molecular Therapy, Department of Pediatrics,
- Powell Gene Therapy Center and Genetics Institute,
- University of Florida Health (US)
- UF Health Cancer Center (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-06-03
- Volume
- 105
- Issue
- 22
- Pages
- 7827-7832
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2402387
- OpenAlex
- W2122236774
- Cited by
- 558
- References
- 53
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 30 · 2023: 31 · 2022: 29 · 2021: 43 · 2020: 38 · 2019: 31 · 2018: 27 · 2017: 34 · 2016: 29 · 2015: 38 · 2014: 34 · 2013: 44 · 2012: 24
- FWCI
- 18.28
- Type
- journal article
- Language
- en
- Update notices
- correction (2008-08-05)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- National Institutes of Health (Project 3)
- National Heart, Lung, and Blood Institute (P01-HL51811, P01HL059412, P01HL051811, R01 HL-07691, R01HL065570, R01HL-65570, P01HL078810)
- National Institute of General Medical Sciences (R01GM082946)
- National Institute of Allergy and Infectious Diseases (R01AI051390)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, R01DK062302)
- National Institute of Biomedical Imaging and Bioengineering (R01EB002073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- tyrosine mutations, proteasomal degradation, nuclear transport, transduction efficiency, factor IX, gene therapy vectors, hepatocytes
- MeSH terms
- Dependovirus, Animals, Capsid, Cell Nucleus, Genetic Vectors, HeLa Cells, Humans, Mice, Inbred C57BL, Phosphorylation, Transduction, Genetic, Tyrosine, Genetic Therapy, Point Mutation, Hepatocytes, Mice, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.